Regeneron's founders focused on building technology platforms for nearly a decade before their first major drug hit. This extreme long-term vision was designed to solve the industry's recurring patent cliff problem by creating a sustainable innovation engine, taking almost 24 years to achieve profitability.

When the industry lost faith in RNAi, Alnylam launched "Alnylam 5x15," a public five-year goal to advance five drugs into the clinic. While it took years to register externally, this bold commitment immediately became a powerful internal rallying cry, injecting hope and focus into the team during a demoralizing period.

Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

Transgene pivoted from "off-the-shelf" to individualized cancer vaccines not by starting over, but by leveraging its deep, four-decade-long expertise in viral vectors and payload integration. This highlights how legacy know-how can be a critical asset in strategic company shifts.

To maintain a competitive edge, BridgeBio only pursues programs that are either "first in class" (a novel treatment where none exists) or "best in class" (a demonstrably superior option, like an oral pill versus a daily injection). This strict strategic filter is the core of their entire R&D pipeline selection process.

Facing industry-wide skepticism in 2010, Alnylam implemented a highly disciplined R&D strategy. They focused exclusively on targets that met strict criteria: liver expression (where delivery worked), human genetic validation (to de-risk biology), and an early biomarker. This strategic focus was key to their survival and success.

Apogee built its strategy around known biological mechanisms, focusing innovation solely on antibody engineering. This allowed them to de-risk assets early and efficiently (e.g., proving half-life in healthy volunteers). This clear, stepwise reduction of risk proved highly attractive to capital markets, enabling them to raise significant funds for late-stage development.

A decade ago, Neurocrine made the difficult decision to pause development of a promising CRF2 agonist. This ruthless prioritization freed up essential capital and focus to successfully develop what became INGREZZA, their blockbuster drug, demonstrating a long-term strategy of sacrificing a good opportunity for a great one.

With patent cliffs looming and mature assets acquired, large pharmaceutical companies are increasingly paying billion-dollar prices for early-stage and even preclinical companies. This marks a significant strategic shift in M&A towards accepting higher risk for earlier innovation.